Taken together, these findings highlight that targeting signaling molecules such as AMPK, IL-1β, IL-18, CSF-1, thrombin, and GPR109A holds promise for effectively reversing peripheral or central sensitization along the pain signaling pathway, ultimately offering relief from chronic pain induced by SLE. The gene discussed is IL1B; the disease is systemic lupus erythematosus.